SCM
XERS icon

Semanteon Capital Management’s Xeris Biopharma Holdings XERS Stock Holding History

Semanteon Capital Management’s Portfolio XERS Stock Details XERS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-32,925
Closed -$268K – 176
2025
Q3 		$268K Buy
+32,925
New +$219K 0.34% 150
2025
Q2 		– Sell
-156,191
Closed -$857K – 288
2025
Q1 		$857K Buy
+156,191
New +$630K 0.47% 92

Other funds holding XERS

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $89.9B AUM 20.22% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Semanteon Capital Management's XERS Position: Q4 2025 in Review

Semanteon Capital Management sold out of Xeris Biopharma Holdings (XERS) in Q4 2025, closing a stake of 32,925 shares — an estimated $268K sold.

Semanteon Capital Management first reported a position in XERS in Q1 2025 and held it in 2 quarters. The position peaked at $857K in Q1 2025. 225 funds tracked by Wall St. Rank hold XERS as of Q4 2025.

  • Semanteon Capital Management reported no remaining Xeris Biopharma Holdings position as of Q4 2025 after selling out during the quarter.
  • Semanteon Capital Management sold 32,925 Xeris Biopharma Holdings shares in Q4 2025, an estimated $268K.
  • Semanteon Capital Management first reported a position in Xeris Biopharma Holdings in Q1 2025 and held it in 2 quarters.
  • Semanteon Capital Management's Xeris Biopharma Holdings position peaked at $857K in Q1 2025.
  • 225 funds tracked by Wall St. Rank held Xeris Biopharma Holdings as of Q4 2025.

Based on Semanteon Capital Management's 13F filing for Q4 2025, filed 10 Feb 2026.